An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

Trial Profile

An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs Esketamine (Primary) ; Duloxetine; Escitalopram; Sertraline; Venlafaxine
  • Indications Major depressive disorder
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms SUSTAIN-2
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 08 Dec 2017 Results of a post-hoc analysis assessing safety and efficacy of semaglutide in elderly versus non-elderly patients across SUSTAIN 1-5 trials (n=3899) presented at the 2017 Congress of the International Diabetes Federation
    • 22 Nov 2017 Status changed from recruiting to completed.
    • 09 Nov 2017 This trial has been completed in Germany (end date: 30 Oct 2017).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top